Hologic Inc (HOLX)

$74.86 -0.15 (-0.20%)
Market Cap 16.68B
Revenue (ttm) 4.10B
Net Income (ttm) 565.70M
EPS (ttm) N/A
PE Ratio 17.53
Forward PE 16.61
Profit Margin 13.80%
Debt to Equity Ratio 0.50
Volume 3,630,395
Avg Vol 3,354,844
Day's Range N/A - N/A
Shares Out 222.91M
Stochastic %K 91%
Beta 0.70
Analysts Sell
Price Target $76.92

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 508 263 2900
Address:
250 Campus Drive, Marlborough, United States
Iightning
Iightning Dec. 4 at 8:19 PM
1ightning® Premium Options Alert (Actionable) Ticker: $HOLX Contract: Dec 19 $72.5C Entry: 2.62 Exit: 3.30 Return: +25.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 6:31 PM
Is $HOLX quietly building a bigger moat in oncology testing? Its BCI test is gaining traction, and new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions — momentum that’s hard to ignore. Full breakdown here 👉 https://www.zacks.com/stock/news/2799647/hologics-bci-test-shows-growing-impact-in-endocrine-therapy-decisions?cid=sm-stocktwits-2-2799647-teaser-23545&ADID=SYND_STOCKTWITS_TWEET_2_2799647_TEASER_23545
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 5:31 PM
$HOLX gaining momentum — is it undervalued? 📈 In just six months, Hologic shares have surged 18.9%, outpacing the industry’s 14% growth. With a forward five-year P/S of 3.87X, it’s trading below the industry average of 4.39X, suggesting potential value. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2799647/hologics-bci-test-shows-growing-impact-in-endocrine-therapy-decisions?cid=sm-stocktwits-2-2799647-body-23521&ADID=SYND_STOCKTWITS_TWEET_2_2799647_BODY_23521
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 5:00 PM
$HOLX AtomicAlerts® Scalp Alert Direction: LONG Entry: $75.07 TP1: $75.77 | TP2: $76.47 | TP3: $77.17 Stop Loss: $74.47 EMA9: 75.08 | EMA21: 75.08 RSI14: 59.92 | VWAP: 75.02 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:26 PM
$HOLX AtomicAlerts® Scalp Alert Direction: LONG Entry: $75.08 TP1: $75.78 | TP2: $76.48 | TP3: $77.18 Stop Loss: $74.48 EMA9: 75.09 | EMA21: 75.08 RSI14: 53.81 | VWAP: 75.01 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 1:49 PM
$HOLX AtomicAlerts® Scalp Alert Direction: SHORT Entry: $75.01 TP1: $74.31 | TP2: $73.61 | TP3: $72.91 Stop Loss: $75.61 EMA9: 75.02 | EMA21: 75.03 RSI14: 34.61 | VWAP: 74.92 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:16 PM
$HOLX AtomicAlerts® Scalp Alert Direction: SHORT Entry: $75.01 TP1: $74.31 | TP2: $73.61 | TP3: $72.91 Stop Loss: $75.61 EMA9: 75.02 | EMA21: 75.03 RSI14: 34.61 | VWAP: 74.92 Paid Alerts: https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 4 at 4:02 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HOLX Contract: Dec 19 $72.5C Entry: 3.17 Exit: 6.11 Return: +92.35% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 8:38 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HOLX Contract: Dec 19 $60C Entry: 15.00 Exit: 28.29 Return: +88.61% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 1 at 10:14 PM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $HOLX **Contract:** Dec 19 $80C **Entry:** 0.25 **Exit:** 0.42 **Return:** **+66.47% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Latest News on HOLX
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration

Dec 2, 2025, 8:10 AM EST - 2 days ago

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration

New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA

Nov 25, 2025, 8:08 AM EST - 9 days ago

New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA

Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking

Nov 12, 2025, 8:11 AM EST - 22 days ago

Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

Nov 3, 2025, 4:01 PM EST - 4 weeks ago

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

Hologic Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX

Oct 22, 2025, 4:56 PM EDT - 6 weeks ago

Hologic Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

Oct 21, 2025, 9:18 AM EDT - 6 weeks ago

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

BX TPG

Blackstone, TPG to acquire medical device maker Hologic in up to $18.3 billion deal

Oct 21, 2025, 8:48 AM EDT - 6 weeks ago

Blackstone, TPG to acquire medical device maker Hologic in up to $18.3 billion deal

BX TPG

Hologic to be Acquired by Blackstone and TPG for up to $79 per Share

Oct 21, 2025, 8:41 AM EDT - 6 weeks ago

Hologic to be Acquired by Blackstone and TPG for up to $79 per Share

Hologic Stock Rises as Report Says Blackstone and TPG in Advanced Takeover Talks

Oct 20, 2025, 7:55 AM EDT - 6 weeks ago

Hologic Stock Rises as Report Says Blackstone and TPG in Advanced Takeover Talks

BX TPG

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025

Oct 2, 2025, 4:04 PM EDT - 2 months ago

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025

Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis

Oct 2, 2025, 8:05 AM EDT - 2 months ago

Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis

New Survey Results Underscore the Need to #BustTheMyth About Mammograms

Sep 30, 2025, 8:15 AM EDT - 2 months ago

New Survey Results Underscore the Need to #BustTheMyth About Mammograms

Volition Signs Co-Marketing and Services Agreement with Hologic

Sep 29, 2025, 9:30 AM EDT - 2 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

VNRX

Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm

Sep 29, 2025, 9:30 AM EDT - 2 months ago

Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm

New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI

Sep 26, 2025, 8:00 AM EDT - 2 months ago

New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI

Blackstone and TPG revive interest in buying Hologic, source says

Sep 17, 2025, 4:41 PM EDT - 2 months ago

Blackstone and TPG revive interest in buying Hologic, source says

BX TPG

Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:05 PM EDT - 3 months ago

Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference

Sep 3, 2025, 4:02 PM EDT - 3 months ago

Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference

Hologic (HOLX) Q3 Revenue Beats 1%

Jul 31, 2025, 5:03 AM EDT - 4 months ago

Hologic (HOLX) Q3 Revenue Beats 1%

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 7:12 PM EDT - 4 months ago

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Hologic raises annual profit forecast on diagnostic and surgical demand

Jul 30, 2025, 6:06 PM EDT - 4 months ago

Hologic raises annual profit forecast on diagnostic and surgical demand

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Jul 30, 2025, 4:01 PM EDT - 4 months ago

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Jul 22, 2025, 5:06 PM EDT - 4 months ago

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Jul 2, 2025, 4:05 PM EDT - 5 months ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

Jun 2, 2025, 11:03 AM EDT - 6 months ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 3:48 PM EDT - 6 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

May 27, 2025, 1:05 PM EDT - 6 months ago

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

BX TPG

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

May 22, 2025, 5:05 PM EDT - 7 months ago

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

Hologic to Webcast Presentations at Upcoming Investor Conferences

May 13, 2025, 4:10 PM EDT - 7 months ago

Hologic to Webcast Presentations at Upcoming Investor Conferences

Hologic: Soft Performance, But Cheap Enough

May 6, 2025, 5:39 PM EDT - 7 months ago

Hologic: Soft Performance, But Cheap Enough

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 8:24 PM EDT - 7 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

May 1, 2025, 6:58 PM EDT - 7 months ago

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

May 1, 2025, 4:01 PM EDT - 7 months ago

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Apr 25, 2025, 4:25 AM EDT - 7 months ago

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Apr 24, 2025, 8:10 AM EDT - 8 months ago

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Apr 22, 2025, 8:08 AM EDT - 8 months ago

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Wayde McMillan Elected to Hologic Board of Directors

Apr 4, 2025, 4:15 PM EDT - 8 months ago

Wayde McMillan Elected to Hologic Board of Directors

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Apr 3, 2025, 4:30 PM EDT - 8 months ago

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Feb 25, 2025, 8:15 AM EST - 10 months ago

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 20, 2025, 3:00 AM EST - 10 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 18, 2025, 8:08 AM EST - 10 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 10:06 PM EST - 10 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Hologic cuts annual revenue forecast on weak demand for breast health products

Feb 5, 2025, 5:56 PM EST - 10 months ago

Hologic cuts annual revenue forecast on weak demand for breast health products

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Feb 5, 2025, 4:01 PM EST - 10 months ago

Hologic Announces Financial Results for First Quarter of Fiscal 2025

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Jan 21, 2025, 8:00 AM EST - 11 months ago

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Hologic: Reasonably, But Not Compellingly Valued

Jan 17, 2025, 1:28 PM EST - 11 months ago

Hologic: Reasonably, But Not Compellingly Valued

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Jan 12, 2025, 4:00 PM EST - 11 months ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Iightning
Iightning Dec. 4 at 8:19 PM
1ightning® Premium Options Alert (Actionable) Ticker: $HOLX Contract: Dec 19 $72.5C Entry: 2.62 Exit: 3.30 Return: +25.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 6:31 PM
Is $HOLX quietly building a bigger moat in oncology testing? Its BCI test is gaining traction, and new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions — momentum that’s hard to ignore. Full breakdown here 👉 https://www.zacks.com/stock/news/2799647/hologics-bci-test-shows-growing-impact-in-endocrine-therapy-decisions?cid=sm-stocktwits-2-2799647-teaser-23545&ADID=SYND_STOCKTWITS_TWEET_2_2799647_TEASER_23545
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 5:31 PM
$HOLX gaining momentum — is it undervalued? 📈 In just six months, Hologic shares have surged 18.9%, outpacing the industry’s 14% growth. With a forward five-year P/S of 3.87X, it’s trading below the industry average of 4.39X, suggesting potential value. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2799647/hologics-bci-test-shows-growing-impact-in-endocrine-therapy-decisions?cid=sm-stocktwits-2-2799647-body-23521&ADID=SYND_STOCKTWITS_TWEET_2_2799647_BODY_23521
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 5:00 PM
$HOLX AtomicAlerts® Scalp Alert Direction: LONG Entry: $75.07 TP1: $75.77 | TP2: $76.47 | TP3: $77.17 Stop Loss: $74.47 EMA9: 75.08 | EMA21: 75.08 RSI14: 59.92 | VWAP: 75.02 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:26 PM
$HOLX AtomicAlerts® Scalp Alert Direction: LONG Entry: $75.08 TP1: $75.78 | TP2: $76.48 | TP3: $77.18 Stop Loss: $74.48 EMA9: 75.09 | EMA21: 75.08 RSI14: 53.81 | VWAP: 75.01 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 1:49 PM
$HOLX AtomicAlerts® Scalp Alert Direction: SHORT Entry: $75.01 TP1: $74.31 | TP2: $73.61 | TP3: $72.91 Stop Loss: $75.61 EMA9: 75.02 | EMA21: 75.03 RSI14: 34.61 | VWAP: 74.92 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:16 PM
$HOLX AtomicAlerts® Scalp Alert Direction: SHORT Entry: $75.01 TP1: $74.31 | TP2: $73.61 | TP3: $72.91 Stop Loss: $75.61 EMA9: 75.02 | EMA21: 75.03 RSI14: 34.61 | VWAP: 74.92 Paid Alerts: https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 4 at 4:02 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HOLX Contract: Dec 19 $72.5C Entry: 3.17 Exit: 6.11 Return: +92.35% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 8:38 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HOLX Contract: Dec 19 $60C Entry: 15.00 Exit: 28.29 Return: +88.61% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 1 at 10:14 PM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $HOLX **Contract:** Dec 19 $80C **Entry:** 0.25 **Exit:** 0.42 **Return:** **+66.47% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
firsthole
firsthole Nov. 29 at 7:01 PM
$HOLX $FEMY Holli swooping in? Serious question?!!
0 · Reply
Vapor83
Vapor83 Nov. 29 at 12:56 AM
$HOLX make a great acquisition $FEMY
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Nov. 26 at 1:51 PM
$HOLX 🩺 1 Hour Levels Price: $74.88 Support: $72.90 Resistance: $76.40
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 1:20 PM
$HOLX's AI in breast imaging — game-changer or just hype? 🤔 🩺 New studies show Hologic's 3DQuorum tech maintains cancer detection rates while streamlining workflows 📊 YTD, shares up 3.8%, compared to industry growth of 4.5% 💡 Forward P/S ratio of 3.86X vs. industry’s 4.40X Discover the full potential here 👉 https://www.zacks.com/stock/news/2795776/new-clinical-evidence-bolsters-hologics-breast-cancer-technologies?cid=sm-stocktwits-2-2795776-body-22507&ADID=SYND_STOCKTWITS_TWEET_2_2795776_BODY_22507
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 12:20 PM
$HOLX showcasing its AI edge — this could turn heads at RSNA 2025. They’re set to present new real-world data showing how their AI-driven breast imaging tools boost workflow efficiency without sacrificing detection. That’s exactly the kind of validation the market loves to see. See the full preview here 👉 https://www.zacks.com/stock/news/2795776/new-clinical-evidence-bolsters-hologics-breast-cancer-technologies?cid=sm-stocktwits-2-2795776-teaser-22501&ADID=SYND_STOCKTWITS_TWEET_2_2795776_TEASER_22501
0 · Reply
Iightning
Iightning Nov. 26 at 1:00 AM
1ightning® Options Trade Alert (Actionable) | Buy $HOLX Dec 19 $75 Call | Enter: $0.12 Exit: $0.18 | Profit: 41.71% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 11:07 AM
1ightning® Options Trade Alert (Actionable) | Buy $HOLX Dec 19 $75 Call | Enter: $0.12 Exit: $0.18 | Profit: 41.71% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 12:02 AM
1ightning® Options Trade Alert (Actionable) | Buy $HOLX Dec 19 $75 Call | Enter: $0.12 Exit: $0.18 | Profit: 41.71% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 9:20 PM
1ightning® Options Trade Alert (Actionable) | Buy $HOLX Dec 19 $75 Call | Enter: $0.09 Exit: $0.12 | Profit: 38.32% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 21 at 7:11 PM
$HLNE $HLT $HMY $HOG $HOLX
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 12:20 PM
$HOLX rides high with a 10.2% fourth-quarter revenue boost in its GYN Surgical segment! 🚀 🔍 Strongest growth in FY25, driven by MyoSure & Fluent sales 🌍 International expansion with MyoSure gaining more market share outside the U.S. 📈 Stock up 8.6% in 3 months, outperforming the industry See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings 👉 https://www.zacks.com/stock/news/2794001/hologics-gyn-surgical-delivers-a-standout-quarter-whats-behind-it?cid=sm-stocktwits-2-2794001-body-21963&ADID=SYND_STOCKTWITS_TWEET_2_2794001_BODY_21963
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 11:20 AM
$HOLX just delivered a breakout quarter in its GYN Surgical segment — this is the kind of acceleration traders chase. MyoSure, Fluent and Gynesonics drove the strongest fiscal 2025 growth for the segment, marking a true standout performance. Full breakdown here 👉 https://www.zacks.com/stock/news/2794001/hologics-gyn-surgical-delivers-a-standout-quarter-whats-behind-it?cid=sm-stocktwits-2-2794001-teaser-21953&ADID=SYND_STOCKTWITS_TWEET_2_2794001_TEASER_21953
0 · Reply